Skip to content

Effect of PESF on speedskaters.

The effect of pulsating electrostatic field on performance level in talented Dutch speedskaters.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22212
Enrollment
20
Registered
2017-10-14
Start date
2017-12-11
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sporters, Athletes Schaatsers, Speedskaters Schaatsen, Speedskating Pulserend elektrostatisch veld, Pulsating electrostatic field (PESF)

Interventions

Treatment: Pulsating electrostatic field therapy for 6 weeks, one treatment of 30 minutes per week. Sham: same procedure as treatment group only with a modified device. Which is turned on but has no

Sponsors

Sponsor Ziekenhuis Tjongerschans Sponsor GLNP life sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age 18 years or older. Skating at a regional and/or national level. Training a minimum of 6 times per week.

Exclusion criteria

Exclusion criteria: Presence of implanted electronic devices (pacemaker). Injuries whereby training and competition are different from normal. Presence of osteosynthesis material (pins, screws, metal plates). Be treated with similar therapy. Signs of infection or acute disease. Possible pregnancy. Participating in another medical research that will be interfering. Signs and symptoms of a possible oncological disease.

Design outcomes

Primary

MeasureTime frame
To analyse the effect of six weeks PESF treatment on aerobic and anaerobic performance, measured with an maximum exercise test on the bicycle ergometer (VO2max and Wingate 30) in speedskaters aged between 18-23.

Secondary

MeasureTime frame
To analyse the effect of PESF on: · personal best times in a speedskating competition after four weeks. · quality of life measured by the RAND-36 questionnaire after six weeks of treatment. · fatigue (locally in the lower extremity and general) measured by an adapted visual analogue scale during the six weeks of treatment with PESF.

Contacts

Public ContactT. Kromdijk
kromdijk_thijs@hotmail.com+31 6 538 677 89

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)